Brokers Set Expectations for Lyra Therapeutics, Inc.'s FY202

Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Rating) – Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for Lyra Therapeutics in a note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst L. Chen forecasts that the company will post earnings of ($1.68) per share for the year. Cantor Fitzgerald has a “Overweight” […]

Related Keywords

Edwardt Anderson , William Blair , Securities Exchange Commission , Zacks Investment Research , Renaissance Technologies , Nasdaq , Lyra Therapeutics Company Profile Get Rating , Nbvm Gp Llc , Cantor Fitzgerald , Lyra Therapeutics Inc , Millennium Management , Lyra Therapeutics , Get Rating , Investment Research , Sigma Advisers , Capital Management , Exchange Commission , Director Edward , Therapeutics Company Profile , Nasdaq Lyra , Elyra , Medical , Earnings Estimates ,